Yolanda E. Hartman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yolanda E. Hartman has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Jason M. Warram
Department of Otolaryngology, The University of Alabama at Birmingham, Birmingham, USA
20 shared publications - Eben Lloyd Rosenthal
Department of Otolaryngology-Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, USA
19 shared publications - Benjamin B. Kasten
Department of Otolaryngology, University of Alabama at Birmingham, Birmingham, USA
18 shared publications - Andrew Fuson
Department of Otolaryngology, University of Alabama at Birmingham, Birmingham, Alabama. 1
17 shared publications - Benjamin Greene
Department of Otolaryngology, University of Alabama at Birmingham, Birmingham, Alabama. 1
17 shared publications - Bharat Panuganti
Department of Otolaryngology–Head and Neck Surgery University of Alabama at Birmingham Birmingham Alabama USA
17 shared publications
Latest Publications
- Open Access
- 29 August 2025
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 18 (11) , 663-675
Contemporary Status and Frontiers of Cervical Cancer Screening in the United States
Cervical cancer screening and its implementation have evolved tremendously since the first method, cytology using the Papanicolaou stain, was introduced in the 1950s. New screening methods, such as human papillomavirus testing, have been discovered, and evidence-based changes have been made to official screening guidelines set forth by various US organizations. With the advent of a human papillomavirus vaccine in 2006 and with more recent research into populations carrying disparate burdens of cervical disease, the effectiveness of current cervical cancer screening programs is being called into question as the disease incidence has not decreased as expected in the past 20 years. This review highlights where cervical cancer screening in the United States started, the current clinical methods, and promising developments on the frontiers of screening research to introduce new screening options or improve current screening programs and outcomes. We also highlight certain population factors that hinder effective screening in high-risk groups, based on research aimed at ensuring that population-wide screening continues to be an effective strategy for reducing cervical cancer incidence and mortality.
- 29 August 2025
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 18 (11) , 663-675
Open AccessContemporary Status and Frontiers of Cervical Cancer Screening in the United States
Cervical cancer screening and its implementation have evolved tremendously since the first method, cytology using the Papanicolaou stain, was introduced in the 1950s. New screening methods, such as human papillomavirus testing, have been discovered, and evidence-based changes have been made to official screening guidelines set forth by various US organizations. With the advent of a human papillomavirus vaccine in 2006 and with more recent research into populations carrying disparate burdens of cervical disease, the effectiveness of current cervical cancer screening programs is being called into question as the disease incidence has not decreased as expected in the past 20 years. This review highlights where cervical cancer screening in the United States started, the current clinical methods, and promising developments on the frontiers of screening research to introduce new screening options or improve current screening programs and outcomes. We also highlight certain population factors that hinder effective screening in high-risk groups, based on research aimed at ensuring that population-wide screening continues to be an effective strategy for reducing cervical cancer incidence and mortality.
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Figure S3: Additional characterization of consecutive OPSCC presentations in a single patient.
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Figure S3: Additional characterization of consecutive OPSCC presentations in a single patient.
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Video S2 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Video S2: Locating missed OPSCC fragment using intraoperative robot fluorescence.
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video S2 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Video S2: Locating missed OPSCC fragment using intraoperative robot fluorescence.
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Video S1 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Video S1: Late-resection intraoperative brightfield and robot fluorescence views of representative OPSCC cases.
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video S1 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Video S1: Late-resection intraoperative brightfield and robot fluorescence views of representative OPSCC cases.
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Table S3: Representativeness of Study Participants.
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Table S3: Representativeness of Study Participants.
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Figure S2: Additional characterization of bipolar forceps instrument and normal tissue fluorescence signals without the tumor in view.
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Figure S2: Additional characterization of bipolar forceps instrument and normal tissue fluorescence signals without the tumor in view.
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Figure S1: OPSCC EGFR H-scores.
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Figure S1: OPSCC EGFR H-scores.
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Figure S2: Additional characterization of bipolar forceps instrument and normal tissue fluorescence signals without the tumor in view.
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Figure S2: Additional characterization of bipolar forceps instrument and normal tissue fluorescence signals without the tumor in view.
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Figure S1: OPSCC EGFR H-scores.
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Figure S1: OPSCC EGFR H-scores.
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Table S2: Surgeon survey assessing the value of fluorescence imaging during the procedure.
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Table S2: Surgeon survey assessing the value of fluorescence imaging during the procedure.